Industry Experts

Xiaodong Yang is the Distinguished Research Fellow at Pyxis Oncology. Before joining Pyxis Oncology, Xiaodong was the founder and Chief Executive Officer of Apexigen (acquired by Pyxis Oncology). Before founding Apexigen, he served as Vice President of Preclinical Development at Intradigm Corporation (acquired by Silence Therapeutics). Xiaodong began his career as a founding scientist at Abgenix, Inc. (acquired by Amgen), where he was Senior Director and headed the Oncology Therapeutic Program Team responsible for setting the strategy and managing the company’s oncology portfolio. While at Abgenix, he served as the project team leader for Vectibix® (panitumumab) and played a key role in its discovery, development, and BLA approval. Xiaodong also managed Abgenix’s partnerships on a number of therapeutic antibody programs. He has over 20 years of experience in leading the research and development of antibody and siRNA therapeutics.
 
Xiaodong was an American Diabetes Association and Juvenile Diabetes Foundation post-doctoral fellow in Microbiology and Immunology at Stanford University School of Medicine. He received his Medical Degree from Beijing Medical University and was awarded his Doctorate in Immunology from the University of Bern in Switzerland.